Cytosorbents

Cytosorbents Corporation
Traded as NASDAQ: CTSO
Industry Critical care
Headquarters Monmouth Junction, New Jersey, USA
Products CytoSorb
Number of employees
 52

CytoSorbents is a critical –care focused publicly traded company (NasdaqCM: CTSO) located in Monmouth Junction, New Jersey.[1][2][3] Cytosorbents has created a blood purification technology based on biocompatible, highly porous polymer beads that act like sponges to remove harmful substances from the blood.[4][5]

CytoSorb, the Company's first product to market, received its CE mark approval in 2011.[6][7] The product is currently used in Europe for critical illnesses such as sepsis, burn injury, trauma, lung injury, and pancreatitis.[8] CytoSorbents is the vertically integrated ISO 13485 certified manufacturer of CytoSorb.[9]

CytoSorbents was awarded a $3.8 million contract by Defense Advanced Research Projects Agency (DARPA) for its “Dialysis-Like Therapeutics” program to treat sepsis by removing cytokines and pathogen-derived toxins.[10] The US Army awarded the Company a $1.15 million small-business innovation research contract to evaluate the technology in burn and trauma.[11] The US Air Force is funding a $3million FDA approved randomized controlled trial in trauma and rhabdomyolysis.[12][13]

References

  1. ↑ "CTSO: Summary for CYTOSORBENTS COR- Yahoo! Finance". YAHOO Finance. Retrieved 9 April 2014.
  2. ↑ "CTSO stock quote – Cytosorbents Corporation stock price – NASDAQ.com". NASDAQ. Retrieved 9 April 2014.
  3. ↑ "CTSO SEC Filings". YAHOO. Retrieved 9 April 2014.
  4. ↑ Baum, Stephanie. "Blood purification device for ICU patients seeks to control cytokine storm". Med City News. Retrieved 2013-05-24.
  5. ↑ "Septic shock secondary to β-hemolytic streptococcus-induced necrotizing fasciitis treated with a novel cytokine adsorption therapy". The International Journal of Artificial Organs. Retrieved 6 May 2014.
  6. ↑ Crutcher, Patrick. "Closer Look: CytoSorbents’ Surprise CE Mark Approval". BioMed Reports. Retrieved 4/1/11. Check date values in: |access-date= (help)
  7. ↑ "With EU Regulatory Approval Gained CytoSorbents Corporation (OTCBB: CTSO) One Step Closer to Goal of FDA Regulatory Approval". OTC Equity. Retrieved 9 April 2014.
  8. ↑ Hyatt, Diccon (2013-07-17). "In Supportive Incubator, CytoSorbents Thrives". US!. Retrieved 9 April 2014.
  9. ↑ "CytoSorbents Corporation Achieves ISO 13485 Certification". CNN Money. Retrieved 9 April 2014.
  10. ↑ "DARPA Dialysis-Like-Therapeutic Program Awards $3.8M to CytoSorbents". Global BioDefense. Retrieved 9 April 2014.
  11. ↑ "CTSO Awarded Ph II U.S. Army Grant". Zacks. Retrieved 9 April 2014.
  12. ↑ "Biotech Product Geared Toward Reducing Deaths in the ICU". Sentinel. Retrieved 9 April 2014.
  13. ↑ "Extracorporeal Therapy for the Removal of Myoglobin Using the CytoSorb in Patients With Rhabdomyolysis". clinicaltrials.gov. Retrieved 6 May 2014.


This article is issued from Wikipedia - version of the Thursday, October 08, 2015. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.